Abstract:
Crystalline form V of the compound of formula (I): 
                                 
characterised by its powder X-ray diffraction diagram.
 
     Medicinal products containing the same which are useful in the treatment of melatoninergic disorders.

Description:
The present invention relates to a new crystalline form V of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, of formula (I): 
                                
a process for its preparation and pharmaceutical compositions containing it.
 
     BACKGROUND OF THE INVENTION 
     Agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, has valuable pharmacological properties. 
     Indeed it has the double feature of being, on the one hand, an agonist of melatoninergic system receptors and, on the other hand, an antagonist of the 5-HT 2C  receptor. Those properties confer activity in the central nervous system and, more especially, in the treatment of severe depression, seasonal affective disorders, sleep disorders, cardiovascular pathologies, pathologies of the digestive system, insomnia and fatigue resulting from jetlag, appetite disorders and obesity. 
     DESCRIPTION OF THE PRIOR ART 
     Agomelatine, its preparation and its therapeutic use have been described in European Patent Specification EP 0 447 285. 
     In view of the pharmaceutical value of this compound, it has been important to be able to obtain it with excellent purity, with well defined crystalline form, perfectly reproducible, which as a result exhibits valuable characteristics in terms of dissolution and formulation and sufficiently stable to allow its storage for long periods without particular requirements for temperature, light, humidity or oxygen level. 
     Patent Specification EP 0 447 285 describes the preparation of agomelatine in eight steps, starting from 7-methoxy-1-tetralone. However, that document does not specify the conditions for obtaining agomelatine in a form that exhibits those characteristics in a reproducible manner. 
    
    
     DETAILED DESCRIPTION OF THE INVENTION 
     The Applicant has now developed a new synthesis process that allows agomelatine to be obtained in a well defined, perfectly reproducible crystalline form that especially exhibits valuable characteristics for dissolution and formulation. 
     More specifically, the present invention relates to the crystalline form V of the compound of formula (I), characterised by the following powder X-ray diffraction diagram, measured using a Siemens D5005 diffractometer (copper anticathode) and expressed in terms of inter-planar distance d, Bragg&#39;s angle 2 theta, intensity and relative intensity (expressed as a percentage of the most intense ray): 
     
       
         
               
               
               
             
               
               
               
             
           
               
                   
               
               
                 2-Theta (°) 
                 d (Å) 
                 Intensité 
               
               
                 exp. 
                 exp. 
                 (%) 
               
               
                   
               
             
             
               
                   
               
             
          
           
               
                 9.84 
                 8.979 
                 17 
               
               
                 12.40 
                 7.134 
                 15 
               
               
                 13.31 
                 6.646 
                 19 
               
               
                 15.14 
                 5.848 
                 18 
               
               
                 15.98 
                 5.543 
                 18 
               
               
                 16.62 
                 5.329 
                 19 
               
               
                 17.95 
                 4.939 
                 100 
               
               
                 18.88 
                 4.697 
                 65 
               
               
                 20.49 
                 4.332 
                 24 
               
               
                 20.99 
                 4.228 
                 34 
               
               
                 23.07 
                 3.852 
                 39 
               
               
                 23.44 
                 3.792 
                 36 
               
               
                 24.28 
                 3.663 
                 58 
               
               
                 25.10 
                 3.545 
                 19 
               
               
                 26.02 
                 3.422 
                 15 
               
               
                 26.82 
                 3.322 
                 19 
               
               
                 27.51 
                 3.239 
                 16 
               
               
                   
               
             
          
         
       
     
     The invention relates also to a process for the preparation of the crystalline form V of the compound of formula (I), which process is characterised in that agomelatine is subjected to a mechanical grinding which is said to be “of high energy”. 
     In the crystallisation process according to the invention it is possible to use the compound of formula (I) obtained by any process. 
     The invention relates also to another process for the preparation of the crystalline form V of the compound of formula (I), which process is characterised in that agomelatine is heated until complete melting, then immediately put at room temperature and simultaneously a small quantity of crystalline form V of compound of formula (I) freshly prepared is added, and the mixture is cooled until crystallisation is complete. 
     Preferably, in that second crystallisation process according to the invention, agomelatine will be melted at 110° C. 
     The amount of crystalline form V added in that second process according to the invention will be preferably contained between 1/100 and 1/50 of agomelatine weight. 
     In that second crystallisation process according to the invention, it is possible to use the compound of formula (I) obtained by any process. 
     An advantage of obtaining that crystalline form is that it allows the preparation of pharmaceutical formulations having a consistent and reproducible composition, which as a result exhibits valuable characteristics in terms of dissolution which is especially advantageous when the formulations are to be used for oral administration. 
     A pharmacological study of the form V so obtained has demonstrated that it has substantial activity in respect of the central nervous system and in respect of microcirculation, enabling it to be established that the crystalline form V of agomelatine is useful in the treatment of stress, sleep disorders, anxiety, severe depression, seasonal affective disorders, cardiovascular pathologies, pathologies of the digestive system, insomnia and fatigue due to jetlag, schizophrenia, panic attacks, melancholia, appetite disorders, obesity, insomnia, pain, psychotic disorders, epilepsy, diabetes, Parkinson&#39;s disease, senile dementia, various disorders associated with normal or pathological ageing, migraine, memory loss, Alzheimer&#39;s disease, and in cerebral circulation disorders. In another field of activity, it appears that the crystalline V form of agomelatine can be used in the treatment of sexual dysfunction, that it has ovulation-inhibiting and immunomodulating properties and that it lends itself to use in the treatment of cancers. 
     The crystalline form V of agomelatine will preferably be used in the treatment of severe depression, seasonal affective disorders, sleep disorders, cardiovascular pathologies, insomnia and fatigue due to jetlag, appetite disorders and obesity. 
     The invention relates also to pharmaceutical compositions comprising as active ingredient the crystalline form V of agomelatine together with one or more appropriate inert, non-toxic excipients. Among the pharmaceutical compositions according to the invention there may be mentioned, more especially, those which are suitable for oral, parenteral (intravenous or subcutaneous) or nasal administration, tablets or dragees, granules, sublingual tablets, gelatin capsules, lozenges, suppositories, creams, ointments, dermal gels, injectable preparations, drinkable suspensions and disintegrable pastes. 
     The useful dosage can be adapted according to the nature and the severity of the disorder, the administration route and the age and weight of the patient. The dosage varies from 0.1 mg to 1 g per day in one or more administrations. 
     The Examples below illustrate the invention but do not limit it in any way. 
     EXAMPLE 1 
     Crystalline form V of N-[2-(7-Methoxy-1-naphthyl)ethyl]acetamide 
     100 g of N-[2-(7-Methoxy-1-naphthyl)ethyl]acetamide are put in a mechanical grinder of the vario-planetary mill type for about 6 hours and the solid obtained is characterised by the following powder X-ray diffraction diagram, measured using a Siemens D5005 diffractometer (copper anticathode) and expressed in terms of inter-planar distance d, Bragg&#39;s angle 2 theta, intensity and relative intensity (expressed as a percentage of the most intense ray): 
     
       
         
               
               
               
             
               
               
               
             
           
               
                   
               
               
                 2-Theta (°) 
                 d (Å) 
                 Intensité 
               
               
                 exp. 
                 exp. 
                 (%) 
               
               
                   
               
             
             
               
                   
               
             
          
           
               
                 9.84 
                 8.979 
                 17 
               
               
                 12.40 
                 7.134 
                 15 
               
               
                 13.31 
                 6.646 
                 19 
               
               
                 15.14 
                 5.848 
                 18 
               
               
                 15.98 
                 5.543 
                 18 
               
               
                 16.62 
                 5.329 
                 19 
               
               
                 17.95 
                 4.939 
                 100 
               
               
                 18.88 
                 4.697 
                 65 
               
               
                 20.49 
                 4.332 
                 24 
               
               
                 20.99 
                 4.228 
                 34 
               
               
                 23.07 
                 3.852 
                 39 
               
               
                 23.44 
                 3.792 
                 36 
               
               
                 24.28 
                 3.663 
                 58 
               
               
                 25.10 
                 3.545 
                 19 
               
               
                 26.02 
                 3.422 
                 15 
               
               
                 26.82 
                 3.322 
                 19 
               
               
                 27.51 
                 3.239 
                 16 
               
               
                   
               
             
          
         
       
     
     EXAMPLE 2 
     Crystalline form V of N-[2-(7-Methoxy-1-naphthyl)ethyl]acetamide 
     4 g of N-[2-(7-Methoxy-1-naphthyl)ethyl]acetamide are put in a ventilated incubator at 110° C. After 1 hour at 110° C., the product is immediately placed at room temperature and seeded with 0.05 g of crystalline form V of N-[2-(7-Methoxy-1-naphthyl)ethyl]acetamide structurally pure obtained by mechanical grinding of high energy. After 5 minutes, the crystallisation is complete and the solid obtained is characterised by the following powder X-ray diffraction diagram, measured using a Siemens D5005 diffractometer (copper anticathode) and expressed in terms of inter-planar distance d, Bragg&#39;s angle 2 theta, intensity and relative intensity (expressed as a percentage of the most intense ray): 
     
       
         
               
               
               
             
               
               
               
             
           
               
                   
               
               
                 2-Theta (°) 
                 d (Å) 
                 Intensité 
               
               
                 exp. 
                 exp. 
                 (%) 
               
               
                   
               
             
             
               
                   
               
             
          
           
               
                 9.84 
                 8.979 
                 17 
               
               
                 12.40 
                 7.134 
                 15 
               
               
                 13.31 
                 6.646 
                 19 
               
               
                 15.14 
                 5.848 
                 18 
               
               
                 15.98 
                 5.543 
                 18 
               
               
                 16.62 
                 5.329 
                 19 
               
               
                 17.95 
                 4.939 
                 100 
               
               
                 18.88 
                 4.697 
                 65 
               
               
                 20.49 
                 4.332 
                 24 
               
               
                 20.99 
                 4.228 
                 34 
               
               
                 23.07 
                 3.852 
                 39 
               
               
                 23.44 
                 3.792 
                 36 
               
               
                 24.28 
                 3.663 
                 58 
               
               
                 25.10 
                 3.545 
                 19 
               
               
                 26.02 
                 3.422 
                 15 
               
               
                 26.82 
                 3.322 
                 19 
               
               
                 27.51 
                 3.239 
                 16 
               
               
                   
               
             
          
         
       
     
     EXAMPLE 3 
     Pharmaceutical Composition 
     
       
         
               
             
               
               
               
               
             
           
               
                   
               
               
                 Formulation for the preparation of 1000 tablets each containing a 
               
               
                 dose of 25 mg: 
               
               
                   
               
             
             
               
                   
               
             
          
           
               
                   
                 Compound of Example 1 or 2 
                 25 
                 g 
               
               
                   
                 Lactose monohydrate 
                 62 
                 g 
               
               
                   
                 Magnesium stearate 
                 1.3 
                 g 
               
               
                   
                 Maize starch 
                 26 
                 g 
               
               
                   
                 Maltodextrines 
                 9 
                 g 
               
               
                   
                 Silica, colloidal anhydrous 
                 0.3 
                 g 
               
               
                   
                 Sodium starch glycolate type A 
                 4 
                 g 
               
               
                   
                 Stearic acid 
                 2.6 
                 g 
               
               
                   
                   
               
             
          
         
       
     
     EXAMPLE 4 
     Pharmaceutical Composition 
     
       
         
               
             
               
               
               
               
             
           
               
                   
               
               
                 Formulation for the preparation of 1000 tablets each containing a 
               
               
                 dose of 25 mg: 
               
               
                   
               
             
             
               
                   
               
             
          
           
               
                   
                 Compound of Example 1 or 2 
                 25 
                 g 
               
               
                   
                 Lactose monohydrate 
                 62 
                 g 
               
               
                   
                 Magnesium stearate 
                 1.3 
                 g 
               
               
                   
                 Povidone 
                 9 
                 g 
               
               
                   
                 Silica, colloidal anhydrous 
                 0.3 
                 g 
               
               
                   
                 Sodium cellulose glycolate 
                 30 
                 g 
               
               
                   
                 Stearic acid 
                 2.6 
                 g